The strategic merger between HAB Pharmaceuticals and Signature Phytochemical Industries was successfully concluded by way of slump sale, which now places both companies under one umbrella entity to facilitate further growth.
Announced in March 2026, the merger is expected to help streamline operations and integrate corporate governance practices within the combined entity. After consolidating the financial statements and accounting for internal sales, the merged entity reports an approximate revenue figure of ₹600 crore.
The merged entity will also benefit from increased manufacturing, R&D activities and speciality drugs including oncology, autoimmune diseases, chronic diseases, and rare diseases.
Manufacturing facilities for expansion initiatives:
HAB Pharmaceuticals was incorporated in 1991, and since then, the company has managed to establish itself in several therapeutic areas such as antibiotics, cardiovascular medicines and nonsteroidal anti-inflammatory drugs. Signature Phytochemical Industries, which was established in 2016, manufactures and exports pharmaceutical tablets, capsules and creams.
With regard to its expansion initiatives, HAB Pharma has planned the construction of two manufacturing plants, and both these plants are anticipated to commence operations from August 2026. While one of these plants would deal with sterile manufacturing, including semaglutide, injectables, prefilled syringes, vials and lyophilized products, the other plant would be an automated closed-loop oral solid dosage plant.
It is expected that the two plants would enhance the manufacturing capacity of the firm along with facilitating the firm’s export activities to Southeast Asia, Latin America and Africa. HAB Pharma has undergone regulatory audits in various countries such as Uganda, Tanzania and Iraq.
Focusing on specialty drugs and exports:
As per Saurabh Agarwal, the Director of HAB Pharma, the merger will be an important milestone in increasing the manufacturing footprint of the company and its standing in niche pharmaceutical segments. He further mentioned that the company will concentrate on developing biologics, specialty generics, and advanced drug delivery mechanisms along with enhancing their export and research and development (R&D) capabilities.
Urvee Garg, the Director of HAB Pharma, commented that the consolidation would lead to a more integrated organization that would better cater to the domestic and international market needs. She also highlighted that the focus of the company was quality manufacturing and affordable health solutions.
The combined entity will now aim to tap into the rapidly growing pharmaceutical markets of Latin America, Central Asia, and Southeast Asia. HAB Pharma aims to grow its revenues to ₹2,500 crore to ₹3,000 crore by 2030 through higher manufacturing capacity, complex dosages, and off-patent molecules.
It was mentioned by the company that their future strategy will include providing affordable drugs for the Indian healthcare industry, along with expanding their international presence via manufacturing and specialized pharmaceuticals.
